secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-08-12T11:15:20+00:00
Accession:  0001193125-26-345732
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q2 net loss narrows to $30.4M; first patient dosed in Phase 3 ALLOHA-2 trial
--------------------------------------------------------------------------------

- Q2 2026 net loss $30.4M vs $37.0M; revenue $1.1M vs $3.1M, down on Amgen collaboration timing.
- Cash $100.2M at 6/30/26 funds ops into Q2 2027; missed debt milestones trigger term loan amortization from Q4 2026.
- First patient dosed in Phase 3 ALLOHA-2 (TSC-101, heme malignancies); topline expected mid-2028.
- Cohort C ALLOHA data: 79% (11/14) complete donor chimerism ~3 weeks post-TSC-101; ~90% (17/19) first-pass manufacturing success.
- TSC-102-A01 and TSC-102-A03 Phase 1 trials expected Q4 2026; solid-tumor IND roadmap by H2 2027 after FDA INTERACT engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/0001193125-26-345732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer